-
Oct 24, 2013, 15:00 PM
by
Michael Croft
Bio-IT World | deCODE genetics’ genomics platform has new life as NextCODE Health. The private company announced it launch yesterday with an exclusive license deCODE’s platform, a leadership team of deCODE alumni, and $15 million in venture financing.
Full story
-
Oct 23, 2013, 14:00 PM
by
Michael Croft
Xconomy | Open source and open systems are experiencing a "moment in the sun" in drug discovery says data commons advocate John Wilbanks.
Full story
-
Oct 23, 2013, 14:00 PM
by
Michael Croft
Forbes | With big pharma cutting R&D budgets, universities will need to step up. The Academic Drug Discovery Consortium (ADDC) hopes to facilitate just that.
Full story
-
Oct 23, 2013, 09:00 AM
by
Michael Croft
Bio-IT World | The latest challenge from the sbv IMPROVER project has launched. The Network Verification Challenge opened last week for submissions from the global scientific community.
Full story
-
Oct 22, 2013, 14:00 PM
by
Michael Croft
Bio-IT World | Bina Technologies has announced the general availability of its all-new RNA-Seq analysis capabilities. This new application delivers fast, accurate and scalable analysis of RNA-Seq datasets on top of the company’s Bina Genomic Analysis Platform.
Full story
-
Oct 22, 2013, 08:00 AM
by
Michael Croft
Bio-IT World | There are plenty of plaudits for organizations in the life sciences that change the industry’s conceptions of what is possible, but one purpose of the Bio-IT World Best Practices Awards is to highlight those who refine those achievements until the merely possible becomes truly practical. That is why Bio-IT World was pleased to award an honorable mention at the 2013 Best Practices Awards to TeselaGen Biotechnology, a startup that spun out from the Berkeley Lab’s Joint BioEnergy Institute (JBEI) in 2011, and Amgen for the development of TeselaGen: j5, an automated platform for designing DNA assembly protocols.
Full story
-
Oct 21, 2013, 15:00 PM
by
Michael Croft
Bio-IT World | The Broad Institute today announced that it has passed Massachusetts state inspection, and can begin processing clinical samples as a CLIA-certified lab.
Full story
-
Oct 21, 2013, 13:00 PM
by
Michael Croft
Bio-IT World News Brief | Foundation Medicine has announced findings from a 24-month, multi-institution collaboration demonstrating the analytic validation of its FoundationOne cancer genomics assay. The results were published in the online edition of Nature Biotechnology.
Full story
-
Oct 21, 2013, 07:00 AM
by
Michael Croft
Bio-IT World | Health care and the life sciences industry’s success ultimately turns on patient investment and compliance. No matter how brilliant the finding, how good the drug, how effective the treatment, it is only as good as the patient’s ability and willingness to participate.
Full story
-
Oct 18, 2013, 14:00 PM
by
Michael Croft
Forbes | Watson, the IBM supercomputer best known for its successful stint as a Jeopardy contestant, has a new gig as a clinical advisor at MD Anderson Cancer Center.
Full story
-
Oct 18, 2013, 07:00 AM
by
Michael Croft
Bio-IT World | Guest Commentary | In today’s doctor’s office, when a physician diagnoses a patient, a number of tests are consulted and the best possible course of treatment is prescribed. Unfortunately there is often limited data that allows the doctor to tailor and customize treatment specifically to a patient's biology and lifestyle. But there are five ways technology will change that over the next decade, bringing personalized medicine to fruition.
Full story
-
Oct 17, 2013, 12:00 PM
by
Michael Croft
Bio-IT World News Brief | Good Start Genetics presented additional data on their GoodStart Select carrier screening test. GoodStart reports that 8.4% of carriers of genetic diseases detected with the Good Start tests would have been missed using other available technologies.
Full story
-
Oct 17, 2013, 08:00 AM
by
Michael Croft
Bio-IT World | Bio-IT World is taking on Europe this December under a new name: Clinical Genomics & Informatics Europe. For our fifth year in Europe, we’re digging specifically into clinical genomics and the informatics that underlie progress. Our sequencing track will cover both clinical exome sequencing and RNA sequencing, and on the informatics side of the house, we’ll look at high-scale computing and genomic informatics. The program is rich with standout speakers. Here are just a few of the presentations we’ve flagged.
Full story
-
Oct 16, 2013, 15:40 PM
by
Michael Croft
Neuron | A team of researchers seeking to pinpoint the genetic cause of a rare disorder of brain growth have implicated deficiencies of the amino acid asparagine in the disease phenotype.
Full story
-
Oct 16, 2013, 12:00 PM
by
Michael Croft
Bio-IT World News Brief | OpenHelix today launched a suite of over 100 online bioinformatics and genomics tutorials that introduce researchers, teachers, and students to biomedical resources that are freely available on the web.
Full story
-
Oct 16, 2013, 11:00 AM
by
Michael Croft
Computerworld | The Apache Software Foundation has released Hadoop 2. The most notable new component is YARN--yet another resource negotiator--which Apache refers to as MapReduce version 2.
Full story
-
Oct 16, 2013, 10:15 AM
by
Michael Croft
Bio-IT World News Brief | This month, Roche began the process of closing its wholly-owned subsidiary 454 Life Sciences, a once-dominant player in next-generation sequencing.
Full story
-
Oct 16, 2013, 09:00 AM
by
Michael Croft
FastCompany | In another 23andMe profile, an author submits a sample from her adopted daughter and gets some of the most challenging results.
Full story
-
Oct 15, 2013, 07:45 AM
by
Michael Croft
Nature Communications | Researchers at the University of Massachusetts Medical School believe it may be possible to stop tumor cells from proliferating by teaching them how to age again.
Full story
-
Oct 14, 2013, 08:00 AM
by
Michael Croft
Nature Chemical Biology | Researchers from McMaster University are bypassing traditional drug discovery methods by targeting the processes through which bacteria synthesize and metabolize nutrients, hoping to find new antibiotic compounds that could destroy pathogens in vivo even though these drugs would not work in the ideal nutrient-rich conditions usually tested in the lab.
Full story